Professor John Boldeman and Professor Barry Allen are congratulated on becoming Officers of the Order of Australia in the 2015 Queen’s Birthday Honours.
Professor John Boldeman received his award “for distinguished service to nuclear science and technology, particularly through the design and construction of the Australian Synchrotron particle accelerator, and as a mentor of young scientists.”
John Boldeman started at the (then) Australian Atomic Energy Commission in 1960 where he carried out research on the nuclear fission process and neutron cross sections. This research was carried out on the 3 MV Van de Graaff accelerator and the nuclear reactor Moata. He also contributed to studies of the characteristics of HIFAR.
In 1988, he managed the purchase, shipment and installation of a second-hand accelerator from Rutgers University which became ANSTO’s very successful ANTARES accelerator, now a state-of-the-art facility for ion beam analysis (IBA) and accelerator mass spectrometry.
He had a lead role in proposing, promoting and designing the Australian Synchrotron in Melbourne. The Synchrotron opened in in 2007 and is used in medical research, environmental sciences, agriculture, minerals exploration, engineering and forensics.
Professor Barry Allen received his award for “For distinguished service to biomedical physics, particularly to radiation oncology and the development of innovative methods of cancer treatment, and to international professional scientific associations.”
Barry Allen joined the then Atomic Energy Commission in 1964 where he carried research on neutron physics and later on biomedical applications of neutrons. In the early 1980’s, he began R&D programs in Boron Neutron Capture Therapy (BNCT) for cancer and In Vivo Body Composition (IVBC) for medicine. He designed an in vivo nude mouse irradiation facility at the Moata reactor at Lucas Heights. He also designed the first human body protein monitor (BPM) in Australia at Lucas Heights, which was installed at Royal North Shore Hospital where it continues to operate today in collaborative clinical studies with most Sydney hospitals.
He was a principal research scientist at St George Cancer Care Centre between 1994 and 2012. The Targeted Alpha Therapy (TAT) project, begun in 1994, was successful in developing new agents for the treatment of melanoma and leukaemia, breast, prostate, pancreatic and colorectal cancers. The phase 1 clinical trial of TAT for metastatic melanoma at St George Hospital showed good tumour regression without significant adverse events. A further development was the biological dosimeter for systemic radiotherapy, based on the formation of micronuclei in lymphocytes.